Alpha1-Blocker Eyedrops for Self-Administered Myopia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for myopia progression are complex and require medical intervention, limiting their accessibility and effectiveness for self-administration.
Innovation Solution
Development of eyedrops containing α1-blockers, such as bunazosin, prazosin, urapidil, silodosin, tamsulosin, doxazosin, terazosin, naftopidil, trimazosin, indoramin, alfuzosin, and corynanthine, or their pharmaceutically acceptable salts, which can be self-administered to suppress myopia progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for myopia progression are used, then myopia progression can be suppressed, but the treatment complexity increases and requires medical intervention
Solution Approach 1:
The patent enables patients to self-administer eyedrops containing alpha1-blockers at home without requiring medical intervention. The treatment system is designed for patient autonomy, where individuals can independently apply the medication to suppress myopia progression, eliminating the need for complex medical procedures or professional administration
2Reliability
If existing treatments for myopia progression are used, then myopia progression can be suppressed, but the accessibility and ease of self-administration are limited
Solution Approach 1:
The invention provides a treatment system that patients can independently administer themselves through simple eyedrop application. The formulation is designed for easy self-application, allowing patients to suppress myopia progression without requiring medical facility visits or professional assistance, thereby significantly improving accessibility and ease of use
3Ease of operation
If simple self-administration methods are used, then ease of operation improves, but the effectiveness in suppressing myopia progression may be reduced
Solution Approach 1:
The patent utilizes alpha1-blockers, which are pharmacological agents that block alpha1-adrenergic receptors. By changing the chemical parameter of the treatment from complex medical procedures to simple pharmacological eyedrops, the invention achieves both ease of self-administration and effective suppression of myopia progression through the specific mechanism of alpha1-receptor antagonism
Data Source
AI summary
Eyedrops for suppressing myopia progression containing an α1-blocker. The α1-blocker is one or more substances selected from a group consisting of bunazosin, prazosin, urapidil, silodosin, tamsulosin, doxazosin, terazosin, naftopidil, trimazosin, indoramin, alfuzosin, moxisylyte, and corynanthine, or pharmaceutically acceptable salts thereof.